We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Firms Should Scrutinize FDA Risk Management Guidances, Experts Say
Firms Should Scrutinize FDA Risk Management Guidances, Experts Say
June 6, 2005
Drugmakers should be prepared to justify their decisions not to follow specific recommendations in the FDA’s recent guidances on minimizing drug-safety risks, say experts, who warn the nonbinding suggestions could be used against firms in court.